Neutropenia  >>  Gazyva (obinutuzumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
NCT01671904: A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Checkmark Venclexta +Gazyva + Rituxan +/- bendamustine in relapsed/refractory CLL at ASH 2016
Dec 2016 - Dec 2016: Venclexta +Gazyva + Rituxan +/- bendamustine in relapsed/refractory CLL at ASH 2016
Checkmark P1 data
Sep 2012 - Sep 2012: P1 data
Completed
1
84
Europe, US
Bendamustine, Obinutuzumab, GA101; RO5072759, Rituximab, MabThera; Rituxan, Venetoclax, ABT-199; GDC-0199
Genentech, Inc., AbbVie (prior sponsor, Abbott)
Chronic Lymphocytic Leukemia
08/18
08/20
NCT03759184: Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

Terminated
1
1
US
rhIL-15, Recombinant human interleukin-15, Obinutuzumab, Gazyva
National Cancer Institute (NCI)
Leukemia, Lymphocytic, Chronic, B-Cell
12/19
10/21
ACE-CL-003, NCT02296918: Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Hourglass Jul 2022 - Dec 2022 : Data from trial for CLL/SLL/PLL
Checkmark From ACE-CL-003 trial in CLL/SLL/PLL
Jul 2021 - Jul 2021: From ACE-CL-003 trial in CLL/SLL/PLL
Checkmark Last patient dosing in P1 trial of acalabrutinib + obinutuzumab in CLL/SLL/PL
Feb 2019 - Feb 2019: Last patient dosing in P1 trial of acalabrutinib + obinutuzumab in CLL/SLL/PL
Active, not recruiting
1
69
US
acalabrutinib, ACP-196, Obinutuzumab, Gazyvaro, Venetoclax, ABT-199, Venclexta, GDC-0199, Rituximab, Rituxan
Acerta Pharma BV
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia
08/21
09/27

Download Options